[HTML][HTML] Receptors and signaling mechanisms for B-lymphocyte activation, proliferation and differentiation–insights from both in vivo and in vitro approaches
R Maddaly, G Pai, S Balaji, P Sivaramakrishnan… - FEBS letters, 2010 - Elsevier
During the last three decades, a number of B-lymphocyte specific surface antigens have
been defined some of which may also show activation/differentiation specific expression …
been defined some of which may also show activation/differentiation specific expression …
Human antibodies for immunotherapy development generated via a human B cell hybridoma technology
J Li, T Sai, M Berger, Q Chao… - Proceedings of the …, 2006 - National Acad Sciences
Current strategies for the production of therapeutic mAbs include the use of mammalian cell
systems to recombinantly produce Abs derived from mice bearing human Ig transgenes …
systems to recombinantly produce Abs derived from mice bearing human Ig transgenes …
In Vitro Biomimetic Model of the Human Immune System for Predictive Vaccine Assessments
DR Drake III, I Singh, MN Nguyen… - Disruptive Science …, 2012 - liebertpub.com
The development of vaccines and immunotherapeutics is hampered by the lack of
appropriate in vitro assays by which to test these compounds against the human immune …
appropriate in vitro assays by which to test these compounds against the human immune …
A study of zearalenone cytotoxicity on human peripheral blood mononuclear cells
The mycotoxin zearalenone (ZEA) is a common contaminant of all major cereal grains
worldwide with estrogenic and anabolic activity. We investigated the in vitro cytopathic …
worldwide with estrogenic and anabolic activity. We investigated the in vitro cytopathic …
Immune responses to all ErbB family receptors detectable in serum of cancer patients
R Bei, L Masuelli, E Moriconi, V Visco, A Moretti… - Oncogene, 1999 - nature.com
Employing NIH3T3 transfectants with individual human ErbB receptor coding sequences as
recombinant antigen sources, we detected by immunoblot analysis specific immunoreactivity …
recombinant antigen sources, we detected by immunoblot analysis specific immunoreactivity …
Monoclonal antibodies that specifically block biological activity of a tumor antigen
L Grasso, NC Nicolaides, PM Sass - US Patent 9,624,297, 2017 - Google Patents
This invention relates to novel monoclonal antibodies that specifically bind to the alpha-
folate receptor. In some embodiments, the antibodies inhibit a biological activity of folate …
folate receptor. In some embodiments, the antibodies inhibit a biological activity of folate …
Cryptic epitopes on α-fetoprotein induce spontaneous immune responses in hepatocellular carcinoma, liver cirrhosis, and chronic hepatitis patients
R Bei, A Budillon, M Gabriella Reale, G Capuano… - Cancer research, 1999 - AACR
To determine α-fetoprotein (AFP) immunogenicity in vivo, the presence of antibodies in sera
of 60 hepatocellular carcinoma, 15 liver cirrhosis, and 15 chronic hepatitis patients was …
of 60 hepatocellular carcinoma, 15 liver cirrhosis, and 15 chronic hepatitis patients was …
Anti-mesothelin antibodies
W Ebel, L Grasso, NC Nicolaides, PM Sass… - US Patent …, 2009 - Google Patents
This invention relates to the use of monoclonal and poly clonal antibodies that speci? cally
bind to and become inter naliZed by mesothelin-positive cells and also induce an immune …
bind to and become inter naliZed by mesothelin-positive cells and also induce an immune …
CX3CR1 receptor is up-regulated in monocytes of coronary artery diseased patients: impact of pre-inflammatory stimuli and renin–angiotensin system modulators
S Apostolakis, E Krambovitis, Z Vlata… - Thrombosis research, 2007 - Elsevier
Fractalkine/CX3CR1 pathway is considered a major modulator of atherosclerosis. In the
present study, expression of CX3CR1 on PBMCs/monocytes of healthy individuals and …
present study, expression of CX3CR1 on PBMCs/monocytes of healthy individuals and …
Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
L Grasso, NC Nicolaides, PM Sass - US Patent 8,124,083, 2012 - Google Patents
This invention relates to the use of monoclonal and poly clonal antibodies that specifically
bind to and have the ability in the alternative to become internalized by cells expressing …
bind to and have the ability in the alternative to become internalized by cells expressing …